Since its formaAon in 2002, the ScoDsh Medicines ConsorAum (SMC) has evaluated over 1000 health technology assessment (HTA) submissions of new medicines or indicaAons for use in Scotland. Unlike most HTA agencies which evaluate only selected products, the SMC evaluates almost all products receiving European markeAng authorizaAon, and aims to do so within 3 months of product launch. Any product that receives markeAng authorizaAon but does not submit to the SMC receives an automaAc non--recommendaAon. The SMC have, therefore, assessed more clinical and cost--effecAveness evidence for medicines than any other HTA organizaAon in the world. Trends in SMC guidance were analyzed to provide insights on likely recommendaAons of new products as manufacturers navigate the UK market. The approval rate of new medicines appears to have increased in recent years and may have been influenced by recent reforms in the SMC process, which aimed to improve paAent access to effecAve therapies, including cancer treatments. Recent changes implemented by the SMC may provide hope to companies preparing to navigate the SMC process with oncology, immunosuppressive, infecAon or musculoskeletal products, but companies with gastrointesAnal or nutriAon products should explore addiAonal analyses to maximize market access opportuniAes in Scotland. Whilst the inclusion of paAent and clinician engagement (PACE) meeAngs add an important perspecAve in the decision making process for end--of--life, orphan and ultra--orphan products, it does add 2--3 months to the Amelines for appraising new products and indicaAons. This is an important consideraAon as evidence submissions will consequently be required up to 6 months ahead of markeAng authorizaAon in order to ensure Amely guidance in Scotland.
All analyses were based on a validated, longitudinal MAP BioPharma database of all published guidance from 2002 to 2014 1,2 . SMC recommendaAons following full submission, resubmissions or abbreviated submissions were reviewed and then subdivided into BriAsh NaAonal Formulary (BNF) categories to provide some insight into the consideraAons that companies should include in their strategic plans. 
